May 14th 2024
The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Uveal and Conjunctival Melanoma: Close Together-but Only Distantly Related
January 15th 2016There has been rapid progress in the treatment of metastasis associated with cutaneous melanoma, including impressive results achieved with targeted molecular therapies and immunotherapies, and it is possible (but still unproven) that patients with metastasis from conjunctival and eyelid melanomas may benefit from these new therapies.
Melanoma Patients Suffer Side Effects of Checkpoint Inhibitors, Yet Maintain QoL
November 19th 2015Advanced melanoma patients successfully treated with a combination of nivolumab and ipilimumab may endure severe side effects, but they do not suffer any clinically meaningful changes in health-related quality of life.